Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 4von Hippel-Lindau Disease 2Prostatic Neoplasms 2Meningioma 2Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Pheochromocytoma 1Parathyroid Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms 1Multiple Endocrine Neoplasia Type 1 1Multiple Endocrine Neoplasia 1Medulloblastoma 1Hypoglycemia 1Hypertension 1Hyperparathyroidism 1Hypercalcemia 1Cancer Diagnosis 1Breast Neoplasms 1

Interventions

Capecitabine 5Temozolomide 4Octreotide 3Magnetic Resonance Spectroscopy 2Leucovorin 2Fluorouracil 2Everolimus 2Cisplatin 2Bortezomib 2Biological Therapy 2Bevacizumab 2vatalanib 1temsirolimus 1sapanisertib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1irinotecan sucrosofate 1gallium Ga 68 dotatate 1dehydroftorafur 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Thalidomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Somatostatinoma × gallium Ga 68 dotatate × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡